3-(1H-1,2,4-triazol-1-yl)-1-propylamine hydrochloride | 794522-91-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(1H-1,2,4-triazol-1-yl)-1-propylamine hydrochloride
• 英文别名: 3-(1H-1,2,4-triazol-1-yl)propan-1-amine hydrochloride；3-(1,2,4-triazol-1-yl)propan-1-amine;hydrochloride
• CAS: 794522-91-1
• 化学式: C₅H₁₀N₄*ClH
• 分子量: 162.622
• InChiKey: VXLOUQUZEAJFKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.05
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  56.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-(1H-1,2,4-triazol-1-yl)-1-propylamine hydrochloride 在 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 作用下， 以 甲醇 、 二甲基亚砜 、 乙酸乙酯 为溶剂， 生成 N¹-(3-(1H-1,2,4-triazol-1-yl)propyl)benzene-1,4-diamine
  参考文献：
  名称：

  WO2021/133689

  摘要：

  公开号：
• 作为产物：
  描述：

  1H-1,2,4-噻唑-1-丙胺 在 盐酸 作用下， 以 甲醇 、 乙醚 为溶剂， 生成 3-(1H-1,2,4-triazol-1-yl)-1-propylamine hydrochloride
  参考文献：
  名称：

  [EN] BENZOXAZOLE ACETONITRILES
  [FR] BENZOXAZOLE ACETONITRILES

  摘要：

  本发明涉及苯并噁唑乙腈，以及含有该苯并噁唑乙腈的药物配方（I）的制备方法。所述苯并噁唑乙腈在治疗由胰岛素抵抗或高甘油三酯引起的代谢紊乱方面具有用途，包括糖尿病II型、葡萄糖耐量不佳、胰岛素抵抗、肥胖、多囊卵巢综合征（PCOS）。A是嘧啶基。L是次级或三级氨基团，或者是含有至少一个来自N、O、S的杂原子的3-8环杂环烷基。R1选择自氢、磺酰基、氨基、CiC6-烷基、C2-C6-烯基、C2-C6-炔基、Cl-C6-烷氧基、芳基、卤素、羧基、氨基羰基、氰基或羟基。

  公开号：

  WO2005026159A1

文献信息

• [EN] AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS<br/>[FR] DERIVES DE CYANURE D'AZOLE METHYLIDENE ET LEUR UTILISATION COMME MODULATEURS DE PROTEINE KINASE
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2003106455A1

  公开（公告）日：2003-12-24

  The present invention is related to azole derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such azole derivatives. Said azole derivatives are modulators of the protein kinase signalling pathways, particularly the one involving c-Jun N-terminal kinase and/or Glycogen Kinase Synthase 3. The present invention is furthermore related to novel azole derivatives as well as to methods of their preparation. X is O, S or NR0, with R0 being H or an unsubstituted or substituted C1 -C6 alkyl; A is 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl group.

  本发明涉及唑衍生物，尤其是用作药物活性化合物的唑衍生物，以及包含这种唑衍生物的药物制剂。所述唑衍生物是蛋白激酶信号通路的调节剂，尤其是涉及c-Jun N端激酶和/或糖原合酶3的那一种。本发明还涉及新颖的唑衍生物以及它们的制备方法。X是O、S或NR0，其中R0是H或未取代或取代的C1-C6烷基；A是2-吡啶基，3-吡啶基，4-吡啶基，吡啶唑基，吡唑啉基，吡嗪基或三嗪基团。
• [EN] LIPOXYGENASE INHIBITORS<br/>[FR] INHIBITEURS DE LIPOXYGÉNASE
  申请人：STANFORD RES INST INT

  公开号：WO2021195346A1

  公开（公告）日：2021-09-30

  Various embodiments of the present disclosure are directed to compounds having Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases, and/or treating associated diseases, such as Alzheimer's disease. In some embodiments, the compounds may be administered to a patient as part of a pharmaceutical formulation.

  本公开的各种实施例涉及具有化学式(I)、化学式(IA)、化学式(IB)、化学式(IC)、化学式(ID)、化学式(IE)和/或其药学上可接受的盐的化合物。这些化合物可适用于抑制脂氧化酶，并/或治疗相关疾病，如阿尔茨海默病。在某些实施例中，这些化合物可作为药物配方的一部分向患者施用。
• [EN] PYRIDINYL ACETONITRILES<br/>[FR] ACÉTONITRILES DE PYRIDINYLE
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2004098607A1

  公开（公告）日：2004-11-18

  The present invention is related to pyridinyl acetonitriles as well as to pharmaceutical formulations containing such pyridinyl acetonitriles. Said pyridinyl acetonitriles are modulators of the protein kinase signalling pathways, particularly the one involving Glycogen Kinase Synthase 3 or JNK. The present invention is furthermore related to methods of preparing pyridinyl acetonitriles. X is a substituted or unsubstituted pyridinyl. G is an unsubstituted or substituted pyrimidinyl or triazinyl.

  本发明涉及吡啶基乙腈以及含有这种吡啶基乙腈的药物配方。所述吡啶基乙腈是蛋白激酶信号通路的调节剂，特别是涉及糖原激酶合成酶3或JNK的信号通路。本发明还涉及制备吡啶基乙腈的方法。X是取代或未取代的吡啶基。G是未取代或取代的嘧啶基或三嗪基。
• [EN] BENZIMIDAZOLE ACETONITRILES<br/>[FR] BENZOXAZOLE ACÉTONITRILES
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2005026155A1

  公开（公告）日：2005-03-24

  The present invention is related to benzimidazole acetonitriles as well as to pharmaceutical formulations containing such benzimidazole acetonitriles of formula (I). Said benzimidazole acetonitriles are useful in the treatment of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type II, inadequate glucosetolerance, insulin resistance, obesity, polycystic ovary syndrome (PCOS) (I). The present invention is furthermore related to methods of preparing ben7.oxazole acetonitriles. G is pyrimidinyl; L is an amino group, or a 3-8 membered heterocycloalkyl, containing at least one heteroatorn selected from N, O, S or L is an acylamino moiety; R1 is selected from the group comprising or consisting of hydrogen, sulfonyl, amino, carboxy, aminocarbonyl, CI-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl or Cl-C6-alkoxy, aryl,halogen, cyano or hydroxy;R2 is selected from the group comprising or consisting of hydrogen, CI -C6-alkyl, C2-C6alkenyl, C2-C6-alkynyl, or CI -C6-alkoxy.

  本发明涉及苯并咪唑乙腈，以及含有该苯并咪唑乙腈的药物配方（I）的制备方法。所述苯并咪唑乙腈可用于治疗由胰岛素抵抗或高血糖介导的代谢紊乱，包括糖尿病II型、葡萄糖耐量不良、胰岛素抵抗、肥胖、多囊卵巢综合征（PCOS）。本发明还涉及制备苯7氧唑乙腈的方法。其中G为嘧啶基；L为氨基，或者含有至少一个来自N、O、S的杂原子的3-8成员杂环烷基，或者L为酰氨基基团；R1选自氢、磺酰基、氨基、羧基、氨基甲酰基、C1-C6烷基、C2-C6烯基、C2-C6炔基、或者C1-C6烷氧基的群；R2选自氢、C1-C6烷基、C2-C6烯基、C2-C6炔基、或者C1-C6烷氧基的群。
• Benzoxazole acetonitriles
  申请人：Schwarz Matthias

  公开号：US20070185104A1

  公开（公告）日：2007-08-09

  The present invention is related to benzoxazole acetonitriles as well as to pharmaceutical formulations containing such benzoxazole acetonitriles pof formula (I). Said benzoxazole acetonitriles are useful in the treatment of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type II, inadequate glucose tolerance, insulin resistance, obesity, polycystic ovary syndrome (PCOS). The present invention is furthermore related to methods of preparing benzoxazole acetonitriles (I). A is a pyrimidinyl.L is a secondary or tertiary amino group, or a 3-8 membered heterocycloalkyl, containing at least one heteroatom. selected from N, O, S or L is an acylamino moiety. R 1 is selected from the group comprising or consisting of hydrogen, sulfonyl, amino, C 1 C 6 -alkYl, C 2 -C 6 -alkenYl, C 2 -C 6 -alkynyl or C 1 -C 6 -alkoxy, aryl, halogen, carboxy, aminocarbonyl, cyano or hydroxy.

  本发明涉及苯并噁唑乙腈，以及含有该类苯并噁唑乙腈的制药配方(I)。所述苯并噁唑乙腈在治疗胰岛素抵抗或高血糖介导的代谢性疾病方面具有用途，包括2型糖尿病、不足的葡萄糖耐受性、胰岛素抵抗、肥胖症、多囊卵巢综合症（PCOS）。本发明还涉及制备苯并噁唑乙腈(I)的方法。其中A是吡咯啉基。L是一个次要或三级氨基团，或一个3-8个成员的杂环烷基，其中至少包含一个杂原子，选择自N、O、S，或L是一个酰胺基团。R1选择自氢、磺酰基、氨基、C1-C6-烷基、C2-C6-烯基、C2-C6-炔基或C1-C6-烷氧基、芳基、卤素、羧基、氨基甲酰基、氰基或羟基组成的群。